BRIM Biotechnology has entered a collaboration and license agreement with Janssen Pharmaceutica, a Johnson & Johnson company, under which the parties will research, develop and commercialize certain compounds identified by Janssen that are targeted for dengue indications.
 
Dr. Haishan Jang, BRIM’s president and chief executive officer, said, “We are extremely excited and enthusiastic about working with Janssen in developing effective treatment for dengue. There is a high unmet medical need in dengue, especially in Asia. With Janssen’s experienced Infectious Diseases team and BRIM’s core competencies in translational sciences and integrated operation management in Asia, we are confident at progressing the compounds toward a high quality affordable drug candidate for Dengue disease.”